Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunomodulating compositions and uses therefor

A composition, cell technology, applied in the direction of drug combination, biochemical equipment and methods, microorganisms, etc.

Inactive Publication Date: 2011-01-19
OPAL THERAPEUTICS
View PDF41 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This suggests that there is antigenic competition between Gag-derived peptides and other SIV proteins and that induction of immunodominant non-Gag T-cell responses by polyprotein HIV vaccines can limit therapeutic or prophylactic Gag-specific T-cell responses development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunomodulating compositions and uses therefor
  • Immunomodulating compositions and uses therefor
  • Immunomodulating compositions and uses therefor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0200] The preparation of T lymphocytes is contacted with the Gag-specific antigen-presenting cells of the invention for a time sufficient to pretreat the T-lymphocytes with Gag antigens or antigens presented by those antigen-presenting cells. This process will preferably be at least about 1 day, and up to about 5 days.

[0201] In some embodiments, a population of Gag-specific antigen-presenting cells is cultured in the presence of a heterogeneous population of T lymphocytes, suitably obtained from peripheral blood together with a plurality of Gag peptides of the invention. These cells are cultured for a period of time under conditions sufficient for antigen-presenting cells to present the peptide or a processed form thereof, and for a subpopulation of antigen-presenting cells-initiating T lymphocytes to respond to the Gag antigen.

[0202] 5. Cell-based therapy or prevention

[0203] The Gag-specific antigen-presenting cells described in Section 3.4 and the Gag-pretreated l...

Embodiment

[0240] Control of viremia after immunization of SIV-infected macaques with peptide-pulsed blood

[0241] OPAL immunotherapy was studied in STV-infected macaques receiving ART. Cynomolgus macaques have an at least equivalent pathogenic course of SIV infection compared with an alternative rhesus macaque model 9，10 . use SIV mac251 Thirty-six macaques were infected and treated three weeks later with the antiretroviral drugs tenofovir and emtricitabine for several weeks. Animals were randomly assigned to peak plasma SIV viral load (VL), Mane-A*10 status (MHC class I genes that increase VL in SIV-infected macaques 11 ), weight and gender into 3 groups. Autologous fresh PBMC were mixed ex vivo with 125 overlapping SIV Gag 15mer peptides (OPAL-Gag) at 10 μg / mL / peptide alone (OPAL-Gag) or 823 SIV 15mer peptides spanning all 9 SIV proteins (OPAL-All) for 1 hr, in antiretroviral Rhesus monkeys were immunized 4 times under the coverage of virus treatment (4th, 6th, 8th, 10th week), ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
diameteraaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

This invention discloses compositions that consist essentially of a Gag polypeptide or at least one portion thereof, and optionally antigen-presenting cells or their precursors, for treating or preventing lentiviral infections including the treatment or prevention of related acquired immunodeficiency diseases. In certain embodiments, the compositions consist essentially of a plurality of overlapping and / or non-overlapping peptides derived from a single Gag polypeptide or from different Gag polypeptides.

Description

technical field [0001] The present invention generally relates to modulation of immune responses. More particularly, the present invention relates to a composition consisting essentially of a Gag polypeptide or at least a portion thereof, and optionally an antigen-presenting cell or precursor thereof, for use in the treatment or prevention of lentiviral infections, including related acquired immunodeficiency diseases treatment or prevention. In certain embodiments, the composition consists essentially of a plurality of overlapping and / or non-overlapping peptides derived from a single Gag polypeptide or derived from different Gag polypeptides. [0002] Bibliographic details for the various numerically cited publications in this specification are listed at the end of this specification. Background technique [0003] Effective immunotherapy approaches for human immunodeficiency virus (HIV) are needed. Drug therapy is associated with significant toxicity throughout life. To ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76A61K39/21A61P37/00A61P37/02A61K39/00
CPCC12N2740/16222A61K39/21C12N2740/16234A61K2039/645C07K14/005A61K2039/5158A61K2039/545A61K2039/57C12N2740/15034A61K39/12A61P31/12A61P31/18A61P37/00A61P37/02A61P37/04A61K39/461A61K2239/38A61K39/464838
Inventor V·伯特R·德罗斯S·肯特
Owner OPAL THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com